Arvinas Strikes Deals With Pfizer, Novartis to Compete in Protein Degrader Space
As its lead oral targeted protein degrader moves through Phase III in partnership with Pfizer, Arvinas signs a licensing deal handing over all rights and responsibilities to Novartis.
Arvinas Strikes Deals With Pfizer, Novartis to Compete in Protein Degrader Space Read More »
